

Table 1 Supplemental: SLNB positive patients and Observation patients AJCC Classification¹⁹

SLNB positive patients									
	N°pt	No ulceration				Ulceration			
N° SLN pos	<u>Pathologic Staging</u>	N1a	N2a	N3	N1a	N2a	N3		
1	69	15	2	8	12	11	21		
2	13	-	2	1	-	6	4		
3	2	-	-	-	-	-	2		
	84	19 IIIA		9 IIIC	29 IIIB		27 IIIC		
Observation patients									
	N°pt	No ulceration				Ulceration			
Regional site of metastases	<u>Pathologic staging</u>	N1b	N2b	N2c	N3	N1b	N2b	N2c	N3
Skin	32	-	-	10	-	-	-	22	-
Lymph nodes	55	11	4	-	9	8	2	-	21
<u>Skin + Lymph nodes</u>	6	-	-	-	5	-	-	-	1
	93	25 IIIB		14 IIIC	54 IIIC				

Table 2 Supplemental: Thick melanoma patients median time to relapse

		Thick melanoma patients				
		Total	Observation patients	SLNB Negative	SLNB Positive	
Median time to relapse (months)	No relapse	40.7 (12.1-190.7)	32.8 (12.1-190.7)	70.5 (13.0-155.8)	41.9 (12.1-129.5)	
	Relapse	Total	11.2 (1.7-163.4)	10.7 (1.7-163.4)	19.5 (1.9-103.6)	9.4 (1.8-98.5)
		regional	10.2 (1.7-122.8)	10.0 (1.7-122.8)	17.0 (2.8-95.0)	8.7 (1.8-48.0)
		distant	12.4 (1.9-163.4)	11.2 (1.9-163.4)	26.8 (1.9-103.6)	9.9 (2.0-98.5)

Table 3 Supplemental: Univariate Cox Regression analyses on DFI and DSS

		DFI			DSS		
		HR	CI.	p	HR	CI	p
Age>65		1.06	0.81-1.38	0.686	1.04	0.75-1.45	0.81
<u>Gender (Male vs Female)</u>		1.34	1.01-1.77	0.040	1.63	1.14-2.32	0.007
Breslow		1.05	1.02-1.08	0.001	1.06	1.02-1.09	0.001
Ulceration		1.62	1.23-2.13	0.001	1.69	1.20-2.39	0.002
Histological Regression		0.61	0.36-0.92	0.04	0.46	0.20-0.99	0.05
Immunotherapy		1.02	0.68-1.51	0.931	1.07	0.68- 1.70	0.741
Primary site	Head neck	1			1		
	Trunk	1.43	0.93-2.19	0.099	1.44	0.83- 2.49	0.190
	Upperextremities	1.26	0.72-2.19	0.417	0.94	0.45- 2.00	0.885
	Lower extremities	1.24	0.80-1.92	0.336	1.21	0.69-2.13	0.490
Sentinel node biopsy vs observation		0.69	0.53-0.90	0.006	0.87	0.63-1.21	0.429
Staging	Observation patients	1			1		
	SLNB Negative	0.53	0.38-0.74	0.000	0.66	0.44-1.00	0.050
	SLNB Positive	0.93	0.68-1.29	0.705	1.20	0.81-1.77	0.353